Even the Washington Post is in on the hype-un-approved-treatments bandwagon.
A recent Health & Science article featuring rosacea entices readers with hints of other drugs that might become available.
The informal article doesn’t mention sansrosa (CD07805/47), oxymetazoline (AGN-199201) or ivermectin (CD5024) by name but I thought it was interesting that even these sorts of fluff pieces will promote treatments that are still to be proven and approved.
Are we as rosacea sufferers so over current treatments that we always grasp for what the future might bring? Is that where we really are ? I wonder.
At least it shows that the Consumers Union and the Washington Post are following rosacea developments closely.
Rosacea, a skin condition, can be triggered by extreme temperatures, exercise, foods
Health & Science, By Consumers Union of United States, Published: March 26
…
What are the best treatments?
Topical prescription drugs including azelaic acid (Azelex, Finacea) and metronidazole (MetroGel, Noritate and their generic cousins) can control eruptions, and low-dose oral antibiotics such as doxycycline (Oracea and generic) can reduce inflammation.
Topical retinoids such as tretinoin (Retin-A and generic) can also help, but they should be reserved for cases that don’t respond to standard care because they can cause dryness or irritation in some patients and are never to be used during pregnancy or if trying to conceive
Other drug treatments under study but not yet approved for rosacea include a redness-reducing ingredient that’s in eyedrops for glaucoma, a blood-vessel constrictor used in decongestant nasal sprays, and a cream that targets Demodex mites.
There’s evidence that laser therapy administered by a dermatologist can help reduce the redness, flushing and visible blood vessels caused by rosacea. Ask whether you’re a candidate for the treatment, which is more expensive than medication and often not covered by insurance.
